By Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

About Dr. Kim

Dr. Yoon Hang Kim is a board-certified physician with over 20 years of clinical experience. He completed a fellowship at the University of Arizona Center for Integrative Medicine under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative and holistic medicine. He specializes in low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of 8 books and more than 25 peer-reviewed articles.

Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com

Why "Natural Mast Cell Stabilizers" Deserve a Closer Look

If you live with mast cell activation syndrome, you have probably come across lists of "natural mast cell stabilizers" — supplements like quercetin, luteolin, and stinging nettle that promise to calm your overactive mast cells without a prescription. Some of these lists circulate with the confidence of a textbook, yet most people sharing them have never paused to ask: how strong is the evidence, really?

The honest answer is more nuanced than a simple yes or no. Several natural compounds genuinely do inhibit mast cell degranulation and mediator release in laboratory experiments. That is not nothing — it is a meaningful starting point. But "inhibits mast cells in a petri dish" is not the same statement as "will stabilize your mast cells when you swallow a capsule." And that gap between bench science and bedside reality matters enormously when you are the one making decisions about your own health.

In this article, I want to walk you through the evidence as it actually stands — compound by compound — so you can have a more informed conversation with your clinician about what belongs in your plan and what still needs more proof.

Preclinical Evidence Is Not Clinical Proof — and That Distinction Matters

Before we look at specific compounds, it helps to understand a distinction that trips up even well-read clients: the difference between preclinical evidence and clinical evidence.

Preclinical evidence means a compound did something promising in a controlled laboratory setting — typically in cultured mast cells sitting in a dish, sometimes in animal models. Researchers expose those cells to a stimulus, add the compound, and measure whether histamine release, tryptase secretion, or cytokine production goes down. When it does, the compound earns a label like "mast cell inhibitor" in the scientific literature.

Clinical evidence means the compound was given to actual human beings — ideally in a well-designed trial — and produced a measurable, meaningful benefit. It means we know the compound survives digestion, reaches the tissues that matter, achieves an effective concentration at the mast cell surface, and does so safely at a tolerable dose.

Those are two very different bars to clear. Thousands of compounds look impressive in cell culture and never make it to a successful clinical trial. That does not mean they are worthless. It means we do not yet know whether their laboratory promise translates to your body. Keeping that distinction in mind will help you read supplement marketing with sharper eyes and have better conversations with your clinician about what is worth trying.

The Compounds: What We Actually Know

Below is an evidence-oriented summary — not a ranking of clinical effectiveness — of natural compounds that have shown mast cell–inhibitory activity in experimental studies. For each one, I have noted what the research shows and, just as importantly, where it falls short.

Luteolin — A flavonoid found in celery, peppers, and chamomile. Laboratory studies show that luteolin inhibits histamine release and the secretion of inflammatory cytokines and chemokines from cultured mast cells, including human mast cell models. It is one of the more consistently studied flavonoids in mast cell research. The limitation: human clinical evidence for treating MCAS specifically remains limited. What a compound does in a dish does not guarantee what it will do when you take it by mouth. (PMC review, 2023)

Quercetin — Probably the most widely recommended natural "mast cell stabilizer" in integrative circles. In experimental models — including human mast cells — quercetin inhibits degranulation and reduces the release of histamine, tryptase, and selected cytokines. Some allergic rhinitis trials exist and show modest benefit, but those trials do not establish efficacy for MCAS as a condition, nor do they prove that the mechanism is mast cell stabilization rather than some other anti-inflammatory effect. (Molecules review, 2019)

Kaempferol — Another flavonoid, found in kale, spinach, and broccoli. It inhibits degranulation and cytokine release in human mast cell models. The evidence is predominantly laboratory-based with no published clinical trials in MCAS populations. (PMC review, 2023)

Myricetin — Present in walnuts, berries, and tea. Like kaempferol, myricetin inhibits degranulation and selected inflammatory mediator release in mast cell models. Also predominantly laboratory evidence. (PMC review, 2023)

Curcumin — The active compound in turmeric. Experimental systems show that curcumin reduces degranulation-associated responses and the release of histamine, leukotrienes, prostaglandins, and cytokines. Some clinical data exist for allergic rhinitis, but direct clinical mast cell effects remain unproven. Bioavailability is also a known challenge with curcumin — much of what you swallow never reaches your bloodstream without specialized formulations. (PMC review, 2023)

Resveratrol — Found in red grapes, berries, and peanuts. It suppresses the release of both preformed and newly synthesized mast cell mediators in experimental models. Clinical allergy data are limited, and it has not been established as a treatment for MCAS. (PMC review, 2023)

EGCG and related tea catechins — Certain catechins from green tea inhibit mast cell activation and mediator release, and O-methylated EGCG has been studied in allergic rhinitis with some promising results. However, these effects are compound- and formulation-specific. Not every green tea product or generic "green tea extract" on a shelf will deliver the same activity. (PMC review, 2023)

Cinnamon extract — Suppresses mast cell mediator release in experimental models, and some allergic rhinitis studies have been reported. Extract composition varies widely between products, and the clinical mechanism is not established. (PMC review, 2023)

Where Stinging Nettle Fits — and Why the Nuance Matters

Stinging nettle (Urtica dioica) deserves its own section because it sits in a different evidentiary category than the flavonoids above — and understanding why tells you something important about how to read supplement research in general.

A frequently cited laboratory study found that nettle extract did several interesting things: it antagonized the histamine H1 receptor, inhibited tryptase enzyme activity, and inhibited COX-1, COX-2, and hematopoietic prostaglandin D2 synthase — enzymes involved in inflammatory mediator production. (Roschek et al., 2009)

Those are potentially relevant effects for someone dealing with MCAS. But here is the critical distinction that most supplement blogs gloss over: these mechanisms are not all the same thing.

H1 receptor antagonism blocks a downstream effect of histamine — it does not necessarily prevent histamine release. In other words, it is acting more like an antihistamine than a mast cell stabilizer. Tryptase inhibition reduces an enzyme's activity after it has been released; it does not, by itself, demonstrate reduced tryptase secretion from the mast cell. These are enzyme and receptor assays, which provide less direct evidence of degranulation inhibition than an experiment that measures mediator release from intact mast cells.

The bottom line: stinging nettle has real laboratory antiallergic activity that may benefit some clients, but its direct mast cell–stabilizing effect is less well established than what we see with compounds like luteolin and quercetin. I would characterize it as "antiallergic activity; direct mast cell stabilization uncertain" — which is a meaningful distinction if precision in your treatment plan matters to you.

What This Means for You

If you are living with MCAS and exploring natural options, here is the honest summary:

Natural compounds with experimental evidence of inhibiting mast cell degranulation and mediator release include luteolin, quercetin, kaempferol, myricetin, curcumin, resveratrol, and selected tea catechins. Stinging nettle has laboratory antiallergic activity, but its direct mast cell–stabilizing effect is less well established.

None of these compounds have been proven in rigorous clinical trials to treat MCAS. That does not mean they are useless — some of my clients find real benefit from quercetin or luteolin as part of a broader plan. But it does mean you should approach them with informed expectations rather than the certainty that social media sometimes projects.

A few practical takeaways worth keeping in mind. First, "natural" does not mean "proven." These are promising compounds with real laboratory science behind them, but laboratory science and clinical proof are not the same thing. Second, not all evidence is equal. A compound that directly blocks mast cell degranulation in a cell culture experiment sits on different evidentiary ground than one that inhibits an enzyme downstream. Third, none of this requires — or establishes — a single shared mechanism like mTOR or autophagy. The reported effects involve multiple signaling pathways and differ by compound, cell type, stimulus, and concentration. Fourth, formulation and quality matter. The green tea extract on a discount shelf is not necessarily delivering the same catechins studied in a laboratory. Similarly, curcumin's well-known bioavailability challenges mean that not every turmeric supplement will achieve meaningful tissue concentrations. Finally, supplements are part of a plan, not the plan. In my practice, natural compounds complement — they do not replace — a thorough diagnostic workup, trigger identification, and individualized treatment strategy.

If you would like to explore whether any of these compounds belong in your MCAS management plan, the best starting point is a conversation with a clinician who understands both the condition and the evidence. For more detailed clinical guidance including protocols, visit ifmsynergy.com.

Important: This article is for educational purposes only and does not constitute medical advice. The information presented here is based on preclinical and early clinical research and should not be used to self-diagnose or self-treat any condition, including mast cell activation syndrome. Always consult with a qualified healthcare provider before starting, stopping, or changing any supplement or treatment.

Yoon Hang Kim, MD, MPH is the author of MCAS: Epidemic in Plain Sight and LDN Primer*, both available on Amazon, and is the founder of the LDN Support Group. For more information, visit www.yoonhangkim.com or www.directintegrativecare.com.*

A Clinician-Oriented Guide to Diagnosis, Pharmacotherapy, and Functional Medicine Considerations

Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician